GT
PRPH

Glenmede Trust’s ProPhase Labs PRPH Stock Holding History

Glenmede Trust’s Portfolio PRPH Stock Details PRPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10
Closed – – 2748
2015
Q1 		$0 Buy
+10
New +$147 ﹤0.01% 2521
2014
Q4 		– Sell
-10
Closed – – 2597
2014
Q3 		$0 Buy
+10
New +$156 ﹤0.01% 2501
2014
Q1 		– Sell
-10
Closed – – 2377
2013
Q4 		$0 Buy
+10
New +$180 ﹤0.01% 2324

Other funds holding PRPH

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VIP
Vantage Investment Partners Kansas City, Missouri $1.45B AUM 18.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Glenmede Trust's PRPH Position: Q2 2015 in Review

Glenmede Trust sold out of ProPhase Labs (PRPH) in Q2 2015, closing a stake of 10 shares.

Glenmede Trust first reported a position in PRPH in Q4 2013 and held it in 3 quarters. The position peaked at $0 in Q1 2015. 13 funds tracked by Wall St. Rank hold PRPH as of Q2 2015.

  • Glenmede Trust reported no remaining ProPhase Labs position as of Q2 2015 after selling out during the quarter.
  • Glenmede Trust sold 10 ProPhase Labs shares in Q2 2015.
  • Glenmede Trust first reported a position in ProPhase Labs in Q4 2013 and held it in 3 quarters.
  • Glenmede Trust's ProPhase Labs position peaked at $0 in Q1 2015.
  • 13 funds tracked by Wall St. Rank held ProPhase Labs as of Q2 2015.

Based on Glenmede Trust's 13F filing for Q2 2015, filed 22 Jul 2015.